Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children

N. A. Halsey, P. J. Chesney, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, M. I. Marks, D. L. Murray, Jr Overall, L. K. Pickering, R. J. Whitley, R. Yogev, G. Peter, C. B. Hall, S. Hadler, R. Breiman, M. C. Hardegree, R. F. Jacobs, N. E. MacDonald, W. A. OrensteinN. R. Rabinovich, B. Schwartz

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


In 1991 and 1992, the US Food and Drug Administration approved two acellular pertussis vaccines combined with diphtheria and tetanus toxoids for use as the fourth and fifth doses after the initial three-dose primary series with the standard whole-cell pertussis vaccine administered at 2, 4, and 6 months of age. Recently completed trials of acellular pertussis vaccines conducted in Europe have documented the efficacy of these vaccines when administered as a primary series in infancy. Based on these studies, two acellular pertussis vaccines, Tripedia (Connaught Laboratories, Swiftwater, PA) and ACEL-IMUNE (Wyeth-Lederle Laboratories, Pearl River, NY), were licensed by the Food and Drug Administration for the initial three-dose series. Additional acellular pertussis vaccines are likely to be licensed for use in infants in the future. The recommendations in this statement supplement previous American Academy of Pediatrics guidelines for the use of acellular pertussis vaccines.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
Issue number2
StatePublished - Feb 1997

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children'. Together they form a unique fingerprint.

Cite this